328 related articles for article (PubMed ID: 16413241)
1. Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans.
Azizi M; Bissery A; Peyrard S; Guyene TT; Ozoux ML; Floch A; Ménard J
Clin Pharmacol Ther; 2006 Jan; 79(1):49-61. PubMed ID: 16413241
[TBL] [Abstract][Full Text] [Related]
2. Vasopeptidase inhibition prevents target organ damage and improves survival in spontaneously hypertensive rats.
Linz W; Schäfer S; Afkham F; Gerl M; Schmidts HL; Rütten H
J Renin Angiotensin Aldosterone Syst; 2006 Sep; 7(3):155-61. PubMed ID: 17094052
[TBL] [Abstract][Full Text] [Related]
3. Vasopeptidase inhibition normalizes blood pressure and restores endothelial function in renovascular hypertension.
Quaschning T; Hocher B; Ruhl S; Kraemer-Guth A; Tilgner J; Wanner C; Galle J
Kidney Blood Press Res; 2006; 29(6):351-9. PubMed ID: 17139187
[TBL] [Abstract][Full Text] [Related]
4. Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy.
Benigni A; Zoja C; Zatelli C; Corna D; Longaretti L; Rottoli D; Maggioni P; Todeschini M; Noris M; Remuzzi G
Kidney Int; 2004 Nov; 66(5):1959-65. PubMed ID: 15496167
[TBL] [Abstract][Full Text] [Related]
5. Physiologic consequences of vasopeptidase inhibition in humans: effect of sodium intake.
Azizi M; Lamarre-Cliche M; Labatide-Alanore A; Bissery A; Guyene TT; Ménard J
J Am Soc Nephrol; 2002 Oct; 13(10):2454-63. PubMed ID: 12239234
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans.
Massien C; Azizi M; Guyene TT; Vesterqvist O; Mangold B; Ménard J
Clin Pharmacol Ther; 1999 Apr; 65(4):448-59. PubMed ID: 10223783
[TBL] [Abstract][Full Text] [Related]
7. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.
Azizi M; Chatellier G; Guyene TT; Murieta-Geoffroy D; Ménard J
Circulation; 1995 Aug; 92(4):825-34. PubMed ID: 7641363
[TBL] [Abstract][Full Text] [Related]
8. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
[TBL] [Abstract][Full Text] [Related]
9. Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100,240, on endocrine and renal functions in healthy volunteers.
Rousso P; Buclin T; Nussberger J; Décosterd LA; La Roche SD; Brunner-Ferber F; Brunner HR; Biollaz J
J Hypertens; 1999 Mar; 17(3):427-37. PubMed ID: 10100082
[TBL] [Abstract][Full Text] [Related]
10. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
Song JH; Lee SW; Suh JH; Kim ES; Hong SB; Kim KA; Kim MJ
Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
[TBL] [Abstract][Full Text] [Related]
11. Effect of contrasted sodium diets on the pharmacokinetics and pharmacodynamic effects of renin-angiotensin system blockers.
Azizi M; Blanchard A; Charbit B; Wuerzner G; Peyrard S; Ezan E; Funck-Brentano C; Ménard J
Hypertension; 2013 Jun; 61(6):1239-45. PubMed ID: 23608658
[TBL] [Abstract][Full Text] [Related]
12. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions.
Burchill LJ; Velkoska E; Dean RG; Griggs K; Patel SK; Burrell LM
Clin Sci (Lond); 2012 Dec; 123(11):649-58. PubMed ID: 22715807
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin I-converting enzyme-dependent and neutral endopeptidase-dependent generation and degradation of angiotensin II contrarily modulate noradrenaline release: implications for vasopeptidase-inhibitor therapy?
Raasch W; Dominiak P; Dendorfer A
J Hypertens; 2005 Aug; 23(8):1597-604. PubMed ID: 16003188
[TBL] [Abstract][Full Text] [Related]
14. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A
Hypertension; 2007 Feb; 49(2):276-84. PubMed ID: 17159081
[TBL] [Abstract][Full Text] [Related]
15. Interruption of prolonged ramipril treatment in hypertensive patients: effects on the renin-angiotensin system.
Stephan D; Grima M; Welsch M; Barthelmebs M; Vasmant D; Imbs J
Fundam Clin Pharmacol; 1996; 10(5):474-83. PubMed ID: 8902551
[TBL] [Abstract][Full Text] [Related]
16. Dose-effect relationship of perindopril 10, 14 and 20mg assessed by urine and plasma AcSDKP levels in mildly sodium-depleted healthy volunteers.
Monge M; Paquet V; Bergerot D; Zhygalina V; Blanchard A
Int J Cardiol; 2016 Nov; 222():648-653. PubMed ID: 27517656
[TBL] [Abstract][Full Text] [Related]
17. Renal hemodynamic and natriuretic effects of concomitant Angiotensin-converting enzyme and neutral endopeptidase inhibition in men.
Regamey F; Maillard M; Nussberger J; Brunner HR; Burnier M
Hypertension; 2002 Sep; 40(3):266-72. PubMed ID: 12215465
[TBL] [Abstract][Full Text] [Related]
18. A double-blind, placebo-controlled study to assess tolerability, pharmacokinetics and preliminary pharmacodynamics of single escalating doses of Z13752A, a novel dual inhibitor of the metalloproteases ACE and NEP, in healthy volunteers.
Bani M; Colantoni A; Guillaume M; Macchi F; Moroni G; Persiani S
Br J Clin Pharmacol; 2000 Oct; 50(4):338-49. PubMed ID: 11012557
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects.
Liao WC; Vesterqvist O; Delaney C; Jemal M; Ferreira I; Ford N; Swanson B; Uderman H
Br J Clin Pharmacol; 2003 Oct; 56(4):395-406. PubMed ID: 12968984
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.
Azizi M; Ménard J; Bissery A; Guyenne TT; Bura-Rivière A; Vaidyanathan S; Camisasca RP
J Am Soc Nephrol; 2004 Dec; 15(12):3126-33. PubMed ID: 15579516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
